BARKA Therapeutics ApS
APSActiveAdvertising protectionCVR 44860627Slotsmarken 11, 2970 HørsholmResearch and experimental development on natural sciences and engineering· NACE 7210Est. 2024 · 2 years old— employees
Loading company…
Overview
BARKA Therapeutics ApS is a Danish APS based in Hørsholm, operating in the Research and experimental development on natural sciences and engineering sector. Incorporated in 2024, the company reported revenue of DKK 0 in its latest annual filing.
Revenue 2025
0K DKK
EBITDA margin
—
Net profit 2025
-880.8K DKK
-670% vs 2024
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
-72.2 %
Very weakAmong the 10% lowest rated companies in the industry
20242025
Liquidity ratioCurrent assets ÷ Short-term debt
17.7×
Very strongAmong the 20% highest rated companies in the industry
20242025
Return on assets (ROA)Net profit ÷ Total assets × 100
-105.1 %
Very weakAmong the 10% lowest rated companies in the industry
20242025
EBITDA — year on year
DKK thousandsKey figures
Annual report 2025| Revenue | 0K DKK | — |
| EBITDA | -961.5K DKK | -1792% |
| Net profit | -880.8K DKK | -670% |
| Total assets | 837.7K DKK | -48% |
| Equity | -605.2K DKK | -320% |
| Employees | — | — |
Company information
Legal name
BARKA Therapeutics ApS
CVR number
44860627
Legal form
Anpartsselskab
Founded
29 May 2024 · 2 years
Share capital
DKK 60,000
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør i forening med bestyrelsesformanden, eller af den samlede bestyrelse
Company purpose
Selskabets formål er at drive forskning og udvikling rettet mod fremstilling og kommercialisering af lægemidler, og dermed beslægtet virksomhed efter ledelsens skøn
(no translation available)
Contact
Address
Slotsmarken 11, 2970 Hørsholm
Phone
+45 2167 8077
Email
kab@hannibal-innovation.com
Advertising protection
Active — opted out of marketing use
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), BARKA Therapeutics ApS reported revenue of DKK 0. The figures on this page draw on 2 annual filings covering 2024 to 2025. The bottom line showed a net loss of DKK 880.8k.
At the end of 2025, current assets covered short-term debt 17.7 times. BARKA Therapeutics ApS is one of 2 companies registered under Research and experimental development on natural sciences and engineering in Denmark.
Financials
Revenue
DKKEBITDA
DKK thousandsIncome statement
DKK thousands| Item | 2025 | 2024 |
|---|---|---|
| Revenue | 0 | 0 |
| Staff expenses | -0 | -0 |
| EBITDA | -962 | -51 |
| Depreciation & amort. | -0 | -0 |
| EBIT | -962 | -51 |
| Net financials | -125 | -70 |
| Profit before tax | -1,087 | -121 |
| Tax | -206 | -7 |
| Net profit | -881 | -114 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
DKK thousands| Item | 2025 | 2024 |
|---|---|---|
| Total assets | 838 | 1,599 |
| Equity | -605 | 276 |
| Long-term debt | 1,395 | 1,270 |
| Short-term debt | 47 | 53 |
| Total debt | 1,443 | 1,324 |
Financial ratios
5-year trendEBITDA margin
<−999 %
20242025
Equity ratio
-72.2 %
Very weakAmong the 10% lowest rated companies in the industry
20242025
Return on equity
—
20242025
Net profit margin
<−999 %
20242025
Asset turnover
0.00×
Very weakAmong the 10% lowest rated companies in the industry
20242025
Debt / equity
—
20242025
Sector performance
18 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Return on assets (ROA)Very weak
Among the 10% lowest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Basic earning power (BEP)Very weak
Among the 10% lowest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Gross marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Not rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on net assets (RONA)Not rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Capacity ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioVery strong
Among the 20% highest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioVery strong
Among the 20% highest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioVery strong
Among the 10% highest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Fixed assets to long-term capitalVery strong
Among the 10% highest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioAverage
Around the average of companies in the same industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Current assets to equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Debt & solvency
Solidity ratioVery weak
Among the 10% lowest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioVery weak
Among the 10% lowest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Income to debtVery weak
Among the 20% lowest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtVery weak
Among the 20% lowest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageWeak
Among the 30% lowest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtVery weak
Among the 20% lowest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginVery weak
Among the 10% lowest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Debt to equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Efficiency & development
Asset turnoverVery weak
Among the 10% lowest rated companies in the industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Equity to contributed capitalVery weak
Among the 10% lowest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityVery weak
Among the 10% lowest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtAverage
Around the average of companies in the same industry
The size of this year's increase or decrease in the company's debt.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Annual reports & filings
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HM Management | Management | 2024 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
KA Chairman | Chairman | 2024 |
CJ Board of Directors | Board of Directors | 2024 |
HM Board of Directors | Board of Directors | 2024 |
OB Board of Directors | Board of Directors | 2024 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 66.67–89.99% | 66.67–89.99% | 2024 | |
| Company | 33.33–49.99% | 33.33–49.99% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
Afyx Capital ApS
BARKA Therapeutics ApS Board network connections
Board members of BARKA Therapeutics ApS also hold positions in 13 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Claus Juan Møller-San Pedro | Board of Directors | 5 companies |
| Karin Absalonsen | Chairman | 4 companies |
| Ole Baadsgaard | Board of Directors | 3 companies |
| Hamed Mozaffari Brodersen | Management | 1 company |
Frequently asked questions
What is the CVR number of BARKA Therapeutics ApS?
BARKA Therapeutics ApS is registered with CVR / Virk under CVR 44860627.
Who is the chairman of BARKA Therapeutics ApS?
Karin Absalonsen chairs the board of BARKA Therapeutics ApS.
Where is BARKA Therapeutics ApS headquartered?
BARKA Therapeutics ApS's registered address is Slotsmarken 11.